

03<sup>rd</sup> November, 2017

The Dy. General Manager (Listing Dept.)  
BSE Limited.,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

**Sub.: Presentation to analysts on un-audited Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2017**

The presentation on un-audited Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2017 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL  
VP (LEGAL) & COMPANY SECRETARY

**Encl.:** As above



# Q2 & H1 FY 2017-18



## Consolidated Revenues for Q2 2017-18

(Rs in Crore)

Particulars	Q2 1718	Q2 1617	Gr%
India	607	496	22%
US	255	322	-21%
Brazil	120	157	-24%
Germany	221	186	19%
Other	135	126	7%
Others (Incl contract Mfg.)	91	141	-36%
<b>Total</b>	<b>1,429</b>	<b>1,429</b>	<b>0%</b>



## Consolidated Revenues for H1 2017-18

(Rs in Crore)

Particulars	H1 1718	H1 1617	Gr%
India	1,071	1,006	6%
US	527	755	-30%
Brazil	301	325	-7%
Germany	423	373	13%
Other	258	241	7%
Others (Incl contract Mfg.)	222	280	-21%
<b>Total</b>	<b>2,803</b>	<b>2,980</b>	<b>-6%</b>

